A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

Phase 1TerminatedNCT00403052

Dynavax Technologies Corporation14 enrolled

Overview

The main objectives of this study are to establish a safe, tolerable and active dose of 1018 ISS administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer. Other objectives also include determining tumor response, time to disease progression, and overall survival in treated patients.

This is a Phase I, open-label study of escalating dose levels of 1018 ISS in combination with irinotecan and cetuximab in patients with previously treated metastatic colorectal cancer. Approximately 15 patients will be treated. The objectives of this study are to establish a safe, tolerable, and active dose of 1018 ISS, determine tumor response, time to disease progression, and overall survival in treated patients. The safety and tolerability of 1018 ISS will be evaluated by periodic laboratory assessments, physical examinations, and compilation of adverse events. Once study patients have been consented, screened, and assigned to one of the dose levels of 1018 ISS, patients will receive two 4 week cycles of 1018 ISS therapy plus irinotecan every other week and cetuximab weekly. Irinotecan and cetuximab will continue thereafter until disease progression, unacceptable toxicity, or until the patient refuses treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colorectal Neoplasms

Interventions

1018 ISS immunostimulatory oligonucleotideDRUG

6 weekly subcutaneous (under the skin) injections

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed, written, informed consent must be obtained from the patient or their legal representative before any study-specific procedures are performed * Confirmed diagnosis of adenocarcinoma of the colon or rectum not amenable to curative surgery * One or more prior systemic therapy regimens for metastatic cancer which must have included a fluoropyrimidine (5-fluorouracil (FU) by infusion or capecitabine), oxaliplatin or irinotecan with or without bevacizumab Exclusion Criteria: * Clinically significant obstructive symptoms, intestinal bleeding, or chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom * History of unstable or deteriorating cardiovascular or cerebrovascular disease within 3 months before the first dose of protocol therapy * Clinical evidence of brain metastases or central nervous system disease * Pregnant or lactating women * Serious medical or psychiatric illness * Malignancy other than colorectal carcinoma within the past 2 years, except curatively treated, superficial skin cancer or carcinoma in situ of the cervix * Patients who have been on any experimental study or anti-tumor therapy, received radiotherapy, or had prior surgery (except venous access device placement) within 28 days before the first dose of protocol therapy

Locations (3)

Premiere Oncology

Santa Monica, California, United States

Lombardi Comprehensive Cancer Center, Georgetown University

Washington D.C., District of Columbia, United States

Center for Cancer and Blood Disorders

Bethesda, Maryland, United States

Outcomes

Primary Outcomes

Occurrence of adverse events

Time frame: 16 weeks

Secondary Outcomes

Time to tumor progression

Time frame: 9 or more weeks

Overall survival time

Time frame: 9 or more weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.